Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

Primary Open-angle Glaucoma Clinical Trial

Official title: A First-In-Human, Open-Label, Dose Escalating, Non-Randomized Study to Assess the Safety and Tolerability of a New Timolol Sustained Release Intraocular Implant (TimoD) in Subjects With Primary Open Angle Glaucoma With Pseudophakia

Status Recruiting

Clinical Trial Summary

The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia. The main questions it aims to answer are how safe the investigational drug is and how the body tolerates it.

The study will also check:

• how safely the implant is placed in and removed from the eye and how the body responds to the procedure,

• how safe different doses of timolol are and how the body handles taking it,

• the amount of Timolol released in the bloodstream,

• if there is any positive effect on the pressure inside the eye.

Clinical Trial Description

Timolol will be delivered through an investigational drug called 'TimoD implant'. This implant is placed inside one eye, the study eye, with the help of an instrument (investigational device) called an injector system.

Three dose ranges of TimoD implant will be tested (low, intermediate, and high) in 3 groups of 6 participants.

The Timolol will be released slowly through the implant for up to 1 year (main phase).

Approximately 1 year after the TimoD implant is placed into the eye and in absence of contraindications, the participants will be invited to continue the study in an extension phase. If the participants agree to enter the extension phase and the study investigator confirms it is safe for them, the TimoD implant will remain in the study eye for one additional year. ;

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Primary Open-angle Glaucoma

• NCT number: NCT06321562
• Study type: Interventional
• Source: EyeD Pharma
• Contact: EyeD Pharma
• Phone: +32 4 229 90 00
• Email: dpo@eyedpharma.com
• Status: Recruiting
• Phase: Phase 1
• Start date: March 1, 2023
• Completion date: July 2027